The funding round was led by IRIS, with participation from Five Arrows. The capital will support the company’s international expansion, specifically scaling operations in the United States, where it has maintained a presence in Cambridge, Massachusetts, since 2022.
Implicity, founded in 2016, develops software for cardiac remote monitoring. Its platform aggregates and analyzes data from cardiac implantable electronic devices and heart failure monitoring systems, regardless of the device manufacturer.
The company reports that its technology has contributed to a 26% reduction in mortality and a 4% decrease in hospitalizations among patients. Currently, the platform is utilized by over 250 medical centers to monitor more than 120,000 patients.
The new investment will also fund the development of next-generation AI algorithms for heart failure prediction. The company aims to consolidate the remote monitoring market and expand its technology into additional medical verticals.
